[CAS NO. 579-13-5] OligomycinA

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [579-13-5]

Catalog

HY-16589

Brand

MCE

CAS

579-13-5

DESCRIPTION [579-13-5]

Overview

MDL	-
Molecular Weight	791.06
Molecular Formula	C45H74O11
SMILES	O=C(/C=C/[C@H](C)[C@@H](O)[C@H](C)C([C@H](C)[C@@H](O)[C@@H]1C)=O)O[C@@]([C@@H]2C)([H])[C@H](C)[C@@]3(CC[C@H](C)[C@H](C[C@H](O)C)O3)O[C@@]2([H])CC[C@@H](CC)/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C1=O

For research use only. We do not sell to patients.

16 Publications Citing Use of MCE

Summary

Oligomycin A (MCH 32), created by Streptomyces , acts as a mitochondrial F ₀ F ₁ -ATPase inhibitor, with a K _i of 1 μM; Oligomycin A shows anti-fungal activity.

IC50 & Target

Ki: 1 μM (F ₀ F ₁ -ATPase) ^[1]

In Vitro

Oligomycin A is a mitochondrial F ₀ F ₁ -ATPase inhibitor with a K _i of 1 μM. Oligomycin A shows cytotoxic to the NCI-60 cell lines, with GI ₅₀ of 10 nM. Oligomycin A also inhibits the activity of Triton X-100-solubilized ATPase with a K _i of 0.1 μM. Furthermore, Oligomycin A has anti-fungal activity ^[1] . Oligomycin A (2.4 µM) inhibits the ability of spermatozoa to achieve feasible in vitro capacitation (IVC), and also suppresses progesterone-induced in vitro acrosome exocytosis (IVAE) as well as the concomitant peaks of O ₂ consumption and ATP levels ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Appearance

Solid

Source

Streptomyces diastatochromogenes

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 126.41 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.2641 mL	6.3206 mL	12.6413 mL
5 mM	0.2528 mL	1.2641 mL	2.5283 mL
10 mM	0.1264 mL	0.6321 mL	1.2641 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (3.16 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: 2.5 mg/mL (3.16 mM); Suspended solution; Need ultrasonic
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (3.16 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Spiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2′-[2H]pyran]-3,9,13-trione, 22-ethyl-3′,4′,5′,6′-tetrahydro-7,11,14,15-tetrahydroxy-6′-[(2R)-2-hydroxypropyl]-5′,6,8,10,12,14,16,28,29-nonamethyl-, (1R,2′R,4E,5′S,6S,6′S,7R,8S,10R,11R,12S,14R,15S,16R,18E,20E,22R,25S,28S,29R)-

Oligomycin A

Spiro[2,26-dioxabicyclo[23.3.1]nonacosane-27,2′-[2H]pyran], oligomycin A deriv.

(1R,2′R,4E,5′S,6S,6′S,7R,8S,10R,11R,12S,14R,15S,16R,18E,20E,22R,25S,28S,29R)-22-Ethyl-3′,4′,5′,6′-tetrahydro-7,11,14,15-tetrahydroxy-6′-[(2R)-2-hydroxypropyl]-5′,6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2′-[2H]pyran]-3,9,13-trione

MCH 32